| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697557 | Cancer Treatment Reviews | 2017 | 44 Pages |
Abstract
Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7-10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
John H. Strickler, Christina Wu, Tanios Bekaii-Saab,